As­traZeneca's res­pi­ra­to­ry team ac­knowl­edges its lat­est set­back, tri­al flops

As­traZeneca’s res­pi­ra­to­ry R&D group has an­oth­er set­back to re­port.

The phar­ma gi­ant’s part­ners at Dy­navax Tech­nolo­gies $DVAX filed a state­ment with the SEC to­day not­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER